Check out our most popular compounded medications! Get Started
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suppository containing lidocaine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing lidocaine are listed in injection, ointment, patch, solution, cream and jelly forms. No lidocaine product of any kind is listed in suppository form.
Suppository bases differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Lidocaine is a local anesthetic that numbs nerves where it is applied, commonly compounded in topical creams, gels, ointments and mouth rinses.
Lidocaine is an amide-type local anesthetic. It blocks sodium channels in nerve cells, which stops nerves from carrying pain signals from the area where it is applied. Many manufactured lidocaine products exist. Injectable lidocaine is FDA-approved for local and regional anesthesia and for acute treatment of certain ventricular arrhythmias. The Lidoderm patch (lidocaine 5%) is FDA-approved for relief of pain associated with post-herpetic neuralgia, and over-the-counter 4% patches are sold for minor aches. Viscous oral solutions, gels and ointments are also manufactured.
A prescriber may order lidocaine compounded when a patient needs a strength or dosage form that is not manufactured, a vehicle that avoids a specific allergen or preservative, or a combination with another active ingredient. Compounded lidocaine preparations are not FDA-approved and require a prescription.
The FDA label for viscous lidocaine 2% carries a boxed warning: in children under 3 years, seizures, cardiopulmonary arrest and death have been reported when the product was not given in strict adherence to the dosing and administration recommendations. Other label warnings include methemoglobinemia, a blood disorder that reduces oxygen delivery, with higher risk in G6PD deficiency, heart or lung disease and infants under 6 months, and toxicity when too much lidocaine is absorbed through large areas, broken skin or long contact; severe liver disease adds to that risk. Do not use lidocaine if you are sensitive to amide-type local anesthetics. Tell your prescriber or pharmacist if you take antiarrhythmics, propranolol, fluvoxamine, nitrates, dapsone or sulfonamides, or use any other lidocaine product, because absorption from all sources adds up. The label advises use in pregnancy only if clearly needed; LactMed states lidocaine is not expected to cause adverse effects in breastfed infants. If you notice burning, blistering, dizziness, confusion or gray or blue skin, stop use and talk to your prescriber or pharmacist.
Lidocaine is a tertiary amine amide local anesthetic and Vaughan-Williams class Ib antiarrhythmic. It blocks voltage-gated sodium channels from the intracellular side; its pKa of 7.7 leaves a useful uncharged fraction at physiologic pH, supporting rapid onset. Hepatic metabolism (CYP1A2 and CYP3A4) yields the active metabolites MEGX and GX; elimination half-life is roughly 1.5 to 2 hours, prolonged in heart failure and hepatic impairment. Protein binding is about 60 to 80 percent, largely to alpha-1-acid glycoprotein. From the Lidoderm patch only about 3 percent of the applied dose is absorbed through intact skin; absorption rises with non-intact skin, larger areas and longer contact.
Labeled indications: injectable lidocaine for infiltration, nerve block, epidural and IV regional anesthesia and for acute ventricular arrhythmias; Lidoderm for post-herpetic neuralgia. Prescribers have ordered lidocaine off label as a chronic and postsurgical pain adjunct and for intravesical instillation in interstitial cystitis (StatPearls). Dosing, surface area and application time are per prescriber. Monitor for methemoglobinemia and systemic toxicity, and account for total lidocaine exposure from all concurrent products. Additive toxicity with class I antiarrhythmics; propranolol raises serum lidocaine; fluvoxamine inhibits CYP1A2. Lidocaine is not a controlled substance.
Wash your hands. If the suppository is soft, chill it in its wrapper in the refrigerator or under cool water for a few minutes, then unwrap it. For rectal use, coat the tip with a water-soluble lubricant (not petroleum jelly), lie on your side with your upper knee bent, and insert it pointed end first past the muscle at the opening. For vaginal use, lie on your back with knees bent and insert it as far as it comfortably goes, by finger or applicator; bedtime use limits leakage, and a panty liner protects clothing. Stay lying down about 15 minutes. Wash your hands.
Suppositories are nonaqueous, so under USP <795> they can carry a beyond-use date of up to 180 days at controlled room temperature or in the refrigerator when no other stability data apply. Storage depends on the base: fatty bases can soften at room temperature and may be labeled for the refrigerator, while polyethylene glycol bases usually do not need refrigeration. Keep them cool so they do not melt, and refrigerate them if your label says to.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Insert 1 unwrapped suppository
